Arcturus Therapeutics Holdings Inc. (ARCT)
Nasdaq · Healthcare · Biotechnology
$14.66+12.51%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $417M
- 52-week range
- $5.50 – $24.17
- 52-week change
- −36.35%
- EPS (trailing)
- −$3.33
- Analyst rating
- 1.4 Strong buy
- Next earnings
- Nov 9, 2026
Fiscal year to Dec 2025
- Revenue
- $82.0M (−46.14%)
- Net income
- −$65.8M
- Operating margin
- −93.0%
- Diluted EPS
- −$2.40
- Free cash flow
- −$74.5M
From the company’s annual report on SEC EDGAR.
About Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Headquarters: San Diego, United States · 106 employees · arcturusrx.com